Upload Avatar (500 x 500)
Xu Yao Zhang
Pharmaceutical Sciences
Fudan University
Shanghai
Language: Chinese, English
Immunotherapy
Drug Development
Tumor
Microenvironment
Cancer
Therapy
Research
Mechanisms
Novel Drugs
Biopharmaceuticals
Areas of Focus
- Development of novel immunotherapy drugs
- Research on the mechanisms of tumor immunotherapy and microenvironment
Work Experience
- 2020.9 – Present - Fudan University, Department of Biopharmaceuticals - Junior Researcher
- 2018.7 – 2020.8 - University of Pennsylvania, Tumor Biology - Postdoctoral Researcher
Academic Background & Achievements
- 2015.9 – 2018.7 PhD: Fudan University, School of Pharmacy
- 2012.9 – 2015.7 Master's: Zhengzhou University, School of Pharmacy
- 2008.9 – 2012.7 Bachelor's: Zhengzhou University, School of Pharmacy
Publications
- Cell Membrane-Derived Vesicle: A Novel Vehicle for Cancer Immunotherapy, Xu C, Ju D*, Zhang X*, 2022
- Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8+ T cells and the exclusion of Treg cells, Wang R, Liu H, He P, An D, Guo X, Zhang X*, Feng M*, 2022
- Chimeric antigen receptor T cell therapy: challenges and opportunities in lung cancer, Xu C, Ju D*, Zhang X*, 2022
- Eradication of Neuroendocrine Tumors by CDH17CAR T Cells Without Toxicity to Normal Tissue, Feng Z, He X, Zhang X, Wu Y, Xing B, Knowles A, Shan Q, Miller S, Hojnacki T, Ma J, Katona BW, Gade TP, Schrader J, Metz DC, June CH, Hua X*, 2022
- Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer, Zhang X, Wang Y, Fan J, Chen W, Luan J, Mei X, Wang S, Li Y, Ye L, Li S, Tian W, Yin K*, Ju D*, 2019
- Insights into CD47/SIRPα axis-targeting tumor immunotherapy, Zhang X, Fan J, Ju D*, 2018
- Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma, Zhang X, Chen W, Fan J, Wang S, Xian Z, Luan J, Li Y, Wang Y, Nan Y, Luo M, Li S, Tian W, Ju D*, 2018
- Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastoma, Zhang X, Wang S, Nan Y, Fan J, Chen W, Luan J, Wang Y, Liang Y, Li S, Tian W, Ju D*, 2018
- Mesoporous silica nanoparticles induced hepatotoxicity via NLRP3 inflammasome activation and caspase-1-dependent pyroptosis, Zhang X, Luan J, Chen W, Fan J, Nan Y, Wang Y, Liang Y, Meng G, Ju D*, 2018
- Targeting CD47 and autophagy elicited enhanced anti-tumor effects in non-small cell lung cancer, Zhang X, Fan J, Wang S, Li Y, Wang Y, Li S, Luan J, Wang Z, Song P, Chen Q, Tian W, Ju D*, 2017
- Synthesis, in vitro and in vivo anticancer activities of novel 4-substituted 1,2-bis(4-chlorophenyl)-pyrazolidine-3,5-dione derivatives, Zhang X, Gu Y, Chen T, Yang D, Wang X, Jiang B, Shao K, Zhao W, Wang C, Wang J, Zhang Q, Liu H*, 2015
Awards
- 2021: Selected for Shanghai Youth Science and Technology Talent 'Sailing Plan'
- 2020: Selected for Shanghai 'Overseas High-Level Talent Introduction Plan'
- 2018: Outstanding PhD Graduate of Shanghai General Higher Education Institutions
- 2017: ESMO Immuno Oncology Congress 2017. Poster Discussion & Travel Award
- 2017: Baosteel Education Scholarship Special Award
- 2017: JSMO Annual Meeting. Oral Presentation & Travel Award
- 2016: ESMO Asia 2016 Congress. Poster Presentation & Travel Award
- 2016: JSMO Annual Meeting. Oral Presentation & Travel Award
- 2015: Outstanding Graduate of Henan General Higher Education Institutions
- 2014: National Graduate Scholarship
